The landscape of preclinical drug discovery is undergoing a profound metamorphosis. For decades, the life cycle of a tissue sample in toxicology was linear and terminal: a pathologist examined a glass slide, generated a report, and the physical specimen was consigned to long-term storage, effectively becoming "dark data."
However, a confluence of digital transformation, advanced artificial intelligence (AI), and a shifting regulatory paradigm is turning these static archives into vibrant, reusable data goldmines. By mining legacy tissue and implementing sophisticated digital pathology workflows, the pharmaceutical industry is moving toward a future where animal testing is not the default, but a measured, data-optimized necessity.
The Evolution of the Digital Slide
The catalyst for this shift was the global pandemic, which acted as an inadvertent stress test for the pathology profession. When lockdowns restricted access to physical laboratories, the transition to digital pathology—previously viewed as a niche efficiency tool—became a survival strategy. Pathologists began working remotely, reading digitized slides on screens rather than peering through ocular lenses.
Once the barrier to digitization was breached, the potential of the "pixels" became clear. As Aleksandra Zuraw, DVM, PhD, a veterinary pathologist at Charles River Laboratories, notes, the digital transition fundamentally changed the nature of the pathology endpoint. "Before, the pathology endpoint was just a report," she explains. "Now you have the digitized slide, which is pixels."
These pixels represent a bridge between traditional histology and molecular science. Researchers are now pairing digitized imagery with legacy pathology reports and molecular measurements to train AI models. These models can identify nuanced patterns linked to molecular changes that were previously invisible to the human eye, transforming a single glass slide into a multi-dimensional dataset capable of answering questions that were not even on the table when the study was originally conducted.
Chronology of a Regulatory Shift
The move away from animal-heavy research is not merely a technological trend; it is a movement codified by law. The chronology of this transition highlights an accelerating pressure to modernize preclinical testing:
- 2022: The FDA Modernization Act 2.0. This landmark legislation marked the first significant move to allow non-animal methods to support applications for human clinical trials, signaling that the regulatory environment was ready to evolve beyond the reliance on animal models.
- April 2024: The Alternative Methods Advancement Project. Charles River Laboratories launched a major initiative dedicated to pioneering alternative methods, formalizing the company’s commitment to reducing, refining, and replacing animal testing.
- April 2025: The FDA Roadmap. The FDA published a comprehensive strategy for reducing animal testing in preclinical safety, starting with specific biologics like monoclonal antibodies. The goal is a three-to-five-year transition period where New Approach Methodologies (NAMs) become the standard.
- September 2026: Expanded Guidance. The FDA released further updates, providing concrete regulatory frameworks for how developers can utilize digital pathology and computational modeling to satisfy safety requirements, effectively clearing the path for widespread adoption.
Virtual Control Groups: Doing More with Less
One of the most immediate impacts of this data-driven approach is the implementation of "virtual control groups." In standard toxicology, a significant portion of animal subjects are designated as controls to establish a baseline for comparison.
"Control animals are always a big fraction of every study," says Dr. Zuraw. By leveraging vast repositories of historical data, researchers can now utilize matched virtual controls instead of live animals. This "simple arithmetic" approach significantly reduces the number of animals required for statistical significance in safety studies.
However, the efficacy of virtual controls relies on rigorous data matching. The team at Charles River is currently focused on generating deep, high-fidelity historical databases that ensure study conditions are comparable, preventing false positives where biological variability is mistaken for a drug-induced effect. As these databases grow, the reliance on concurrent control animals is expected to drop significantly.
The Archival Renaissance: Molecular Insights from FFPE
The backbone of modern toxicology remains the formalin-fixed, paraffin-embedded (FFPE) block. These blocks, stored by the millions in labs globally, contain the molecular history of countless failed and successful drug candidates.
Traditionally, if a researcher wanted to understand the molecular mechanism behind an organ-specific toxicity observed in a past study, they would often have to initiate a new animal experiment to collect fresh, frozen tissue suitable for molecular analysis. Today, that is changing. The OECD’s 2025 guidance on sample collection for "omics" analysis provides a roadmap for extracting meaningful molecular information—including gene expression and protein data—from stored FFPE samples.
"Now you have the option to use FFPE material that was already part of a lot of studies for additional information," Dr. Zuraw observes. "You don’t lose the context of the study." By cross-referencing molecular findings from archived tissue with original dosing records and observational data, researchers can gain insights that previously required fresh animal subjects, essentially recycling biological information.
Technological Implications: Virtual Staining and AI
Beyond archival data, the field is embracing "virtual staining." This cutting-edge process involves using AI to generate the appearance of traditional stains on unstained tissue sections, potentially bypassing the need for physical slides altogether.
As demonstrated by recent research and the proliferation of digital pathology startups, virtual staining is moving from experimental demos to standardized clinical and research use. When combined with predictive AI models that can infer molecular states directly from H&E-stained digital slides, the pathology workflow becomes significantly more efficient.
Dr. Zuraw describes this as a potential "snowball effect." As labs invest in the infrastructure required to digitize, share, and analyze these slides, the barriers to adopting more advanced, less invasive methodologies continue to fall. The focus is shifting toward "extracting more from the same animals, from the same blocks, without running a new experiment."
Implications for the Future of Drug Discovery
The shift toward digital pathology and data mining represents a fundamental change in the philosophy of drug discovery. The implications are three-fold:
- Economic and Temporal Efficiency: By reducing the need for new animal studies, pharmaceutical companies can lower the immense costs and time associated with preclinical safety assessments.
- Scientific Robustness: Digital datasets allow for more complex longitudinal studies and the integration of data across different types of experiments, leading to a more holistic understanding of drug toxicity.
- Ethical Responsibility: As regulatory bodies like the FDA move toward making NAMs the default, the industry is aligning its practices with broader societal expectations regarding animal welfare.
However, the transition is not without its hurdles. Dr. Zuraw emphasizes that success depends on "early adopters" who are willing to navigate the complexities of these new methods. These pioneers are essential for generating the precedents that will allow regulatory bodies to refine their guidance and for other labs to implement these technologies without "reinventing the wheel."
Ultimately, the digital pathology movement is proof that the future of drug discovery lies not just in the development of new tools, but in our ability to look back at the information we already have. By treating our archival tissue not as trash, but as a living library of biological truth, we are not only sparing future animals but accelerating the pace at which safe, effective therapies reach patients.
About the Author
